Mesenbio

• 10/01/2024
• Unknown
• $1,781,000

We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics.
Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency and efficacy, which is where we come in. Our suite of immortal MSC lines represent an endless source of therapeutically active EVs, eliminating the need for donor source material. Combined with an in-house chemically defined medium, we can provide improved batch consistency, while reducing cost of goods and reducing regulatory burden.
Our initial target is osteoarthritis, which presents an unprecedented socioeconomic burden as populations age and no disease modifying drugs exist. With our MSC-derived EVs, we have shown that we can exert a strong anti-inflammatory effect, with the added capability of specific cargo delivery.
Our MSC-EV production platform is an agile, versatile means of producing therapeutic EVs for any application at improved consistency.

---

---